Insight, China's Pharmaceutical Industry

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC

Shanghai Simnova Biotech Co., Ltd. announced that its self‑developed anti‑DLL3 chimeric antigen receptor T‑cell (CAR‑T)...

Company Drug

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

Fineline Cube Nov 3, 2025

Akeso Inc. (HKG: 9926) announced that its proprietary bispecific antibody ivonescimab (AK112) has been granted...

Company Deals

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

Fineline Cube Nov 3, 2025

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...

Policy / Regulatory

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Fineline Cube Nov 3, 2025

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) confirmed that...

Company Deals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Fineline Cube Nov 3, 2025

Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...

Company Drug

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Fineline Cube Oct 31, 2025

Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has...

Company Deals Drug

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Fineline Cube Oct 31, 2025

Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...

Company Deals

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

Fineline Cube Oct 31, 2025

China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...

Company

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Fineline Cube Oct 31, 2025

US‑based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third‑quarter 2025 earnings, showing a modest 2%...

Company

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

Fineline Cube Oct 31, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today announced its third‑quarter 2025 financial results. Total revenues reached...

Company

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Fineline Cube Oct 31, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third‑quarter 2025 financial results,...

Company

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Fineline Cube Oct 31, 2025

Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded...

Company Drug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Fineline Cube Oct 31, 2025

Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...

Company Medical Device

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Fineline Cube Oct 31, 2025

Shanghai Bio‑Heart Biological Technology Co., Ltd. (HKG: 2185) announced that its subsidiary, Shanghai AngioCare Medical...

Company Drug

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026

Fineline Cube Oct 31, 2025

Transcenta Holding Limited (HKG: 6628) announced that its joint venture, Inhibrx Biosciences, Inc. (NASDAQ: INBX),...

Company Drug

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Fineline Cube Oct 31, 2025

HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...

Others

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

Fineline Cube Oct 31, 2025

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...

Company Deals

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Fineline Cube Oct 31, 2025

BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...

Company

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

Fineline Cube Oct 31, 2025

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...

Company Deals Drug

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Fineline Cube Oct 31, 2025

JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...

Insight, China's Pharmaceutical Industry

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories